Eli Lilly and Novo Nordisk currently dominate the market for the new class of GLP-1 receptor agonist medications, which work by mimicking the effect of a gut hormone that reduces appetite.

Eli Lilly announced that it is expanding its offerings of its hit weight loss drug Zepbound on Tuesday, a few days after the Food and Drug Administration lifted a shortage on Novo Nordisk’s Wegovy and ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...